Document is current
Any future updates will be listed below
-
Authors
Lu, Amy D.
Chavez, Catia
Daugherty, Stacie L.
Dhar, Pradeep
Derington, Catherine G.
Everhart, Rachel
Morse, Erica F.
Novins-Montague, Sylvie
Trinkley, Katy E.
Waughtal, Joy M.
Zucker, Rachel
Carey, Evan
Bull, Sheana
Peterson, Pamela N.
Ho, P. Michael
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (4UH3HL168504-02)
- License Information
-
More Information
Article History
Received: 11 August 2025
Accepted: 9 February 2026
First Online: 20 February 2026
Declarations
:
: As described in detail in the protocol, all eligible patients are initially assumed to be interested in study participation unless they explicitly opt out. If patients do not opt out during the designated opt-out period, the study team will reach out to the patient via various modalities to explicitly have them opt in to receiving text messages. At any point in the study, patients may request to stop receiving text messages by texting “STOP”. This study was reviewed and approved by the Colorado Multiple Institutional Review Board, protocol #22–2097 (available upon request).
: Not applicable.
: Dr. Sheana Bull is President and a Co-Founder of Clinic Chat, LLC, the company implementing the chatbot described in this article. Dr. Daugherty is supported by grant funding from the National Institutes of Health and Kaiser Permanente Colorado. Dr. Daugherty receives royalties from UpToDate for authorship on educational content unrelated to this project.The remaining authors declare that they have no competing interests.
